loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Filgotinib

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Filgotinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 16,639Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Galapagos announces first quarter 2023 financial results
    Galapagos announces first quarter 2023 financial results

    04 May 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/05/04/2661990/0/en/Galapagos-announces-first-quarter-2023-financial-results.html

    GLOBENEWSWIRE
    04 May 2023
    Share Share
    Galapagos initiates Phase 3 program with filgotinib in patients with AAS
    Galapagos initiates Phase 3 program with filgotinib in patients with AAS

    26 Apr 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/04/26/2655620/0/en/Galapagos-initiates-Phase-3-program-with-filgotinib-in-patients-with-active-axial-spondyloarthritis.html

    GLOBENEWSWIRE
    26 Apr 2023
    Share Share
    Galapagos announces results from PIII trial of filgotinib in Crohn’s disease
    Galapagos announces results from PIII trial of filgotinib in Crohn’s disease

    09 Feb 2023

    // PRESS RELEASE

    https://www.glpg.com/press-release/3766/galapagos-announces-topline-results-from-phase-3-diversity-trial-of-filgotinib-in-crohn-s-disease

    PRESS RELEASE
    09 Feb 2023
    Share Share
    EMA backs restrictions on certain immune-regulating drugs
    EMA backs restrictions on certain immune-regulating drugs

    12 Nov 2022

    // BIOPHARMADIVE

    https://www.biopharmadive.com/news/ema-recommends-jak-inhibitors-restrictions/636343/

    BIOPHARMADIVE
    12 Nov 2022
    Share Share
    Galapagos announces strategy to accelerate innovation & reports 3Q 2022 results
    Galapagos announces strategy to accelerate innovation & reports 3Q 2022 results

    04 Nov 2022

    // PRESS RELEASE

    https://www.glpg.com/press-release/3705/galapagos-announces-strategy-to-accelerate-innovation-and-reports-strong-third-quarter-2022-results

    PRESS RELEASE
    04 Nov 2022
    Share Share
    JAK inhibitors increase risk of cardiovascular problems and cancer, warns PRAC
    JAK inhibitors increase risk of cardiovascular problems and cancer, warns PRAC

    01 Nov 2022

    // Catherine Eckford EUROPEANPHARMACEUTICALREVIEW

    https://www.europeanpharmaceuticalreview.com/news/175849/jak-inhibitors-unsafe-for-cardiovascular-cancer-risk-prac/

    Catherine Eckford EUROPEANPHARMACEUTICALREVIEW
    01 Nov 2022
    Share Share